16:22 EDT Edwards Lifesciences (EW) backs FY24 revenue growth view 8%-10%, consensus $1.44B
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Notable companies reporting after market close
- Edwards Lifesciences options imply 8.1% move in share price post-earnings
- Edwards Lifesciences Corp. (EW) Q3 Earnings Cheat Sheet
- Johnson & Johnson reported strong earnings beat, says Barclays
- December 13, 2024 Deadline: Contact Levi & Korsinsky LLP to Join Class Action Suit Against EW